Johnson & Johnson (JNJ) Stock Price, News & Analysis

Company Overview

Johnson & Johnson (NYSE: JNJ) is a diversified global healthcare company that develops, manufactures and sells a broad range of products in three primary business segments: Pharmaceuticals, Medical Devices and Consumer Health. Founded in 1886 by brothers Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson, the company pioneered sterile surgical dressings and has since expanded into prescription medicines, diagnostics and advanced medical technologies, as well as over-the-counter healthcare products.

In its Pharmaceuticals segment, Johnson & Johnson researches and commercializes treatments in areas such as immunology, oncology, neuroscience and infectious diseases. The Medical Devices segment offers a wide array of surgical systems, orthopaedic devices, cardiovascular care solutions and vision care products. Within Consumer Health, the company markets well-known brands in skin care, baby care, wound care, oral hygiene and women’s health. Together, these divisions serve healthcare professionals, consumers and patients around the world.

Headquartered in New Brunswick, New Jersey, Johnson & Johnson operates in more than 60 countries and sells products in virtually every market worldwide. The company maintains research and development facilities across North America, Europe and Asia, supporting collaborations with academic institutions and biotechnology firms. As of 2022, Johnson & Johnson is led by Chairman and Chief Executive Officer Joaquin Duato, under whose leadership the company continues to pursue innovation and sustainable growth within the global healthcare industry.

Key Stats

• Today's Range: $192.33 to $194.48
• 50-Day Range: $172.79 to $193.27
• 52-Week Range: $140.68 to $194.48
• Volume: 4.15 million shs
• Average Volume: 8.92 million shs
• Market Capitalization: $466.68 billion
• P/E Ratio: 18.70
• Dividend Yield: 2.68%
• Price Target: $200.06
• Consensus Rating: Moderate Buy

Johnson & Johnson Stock Analysis - MarketRank™

Johnson & Johnson scored higher than 97% of companies evaluated by MarketBeat, and ranked 33rd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Johnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 14 buy ratings, 8 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Johnson & Johnson is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Johnson & Johnson has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.63%

Earnings Growth

Earnings for Johnson & Johnson are expected to grow by 4.63% in the coming year, from $10.58 to $11.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Johnson & Johnson is 18.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 43.68.

Price to Earnings Ratio vs. Sector

The P/E ratio of Johnson & Johnson is 18.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.47.

Price to Earnings Growth Ratio

Johnson & Johnson has a PEG Ratio of 2.27. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Johnson & Johnson has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.75% of the float of Johnson & Johnson has been sold short.

Short Interest Ratio / Days to Cover

Johnson & Johnson has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Johnson & Johnson has recently decreased by 17.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Johnson & Johnson pays a meaningful dividend of 2.69%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Johnson & Johnson has been increasing its dividend for 64 years.

Dividend Coverage

The dividend payout ratio of Johnson & Johnson is 50.19%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 46.97% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.98

Percentage of Shares Shorted

0.75% of the float of Johnson & Johnson has been sold short.

Short Interest Ratio / Days to Cover

Johnson & Johnson has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Johnson & Johnson has recently decreased by 17.55%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.00

News Sentiment

Johnson & Johnson has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 174 news articles for Johnson & Johnson this week, compared to 54 articles on an average week.

Search Interest

193 people have searched for JNJ on MarketBeat in the last 30 days. This is an increase of 28% compared to the previous 30 days.

MarketBeat Follows

86 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 132% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,041,109.00 in company stock.

Percentage Held by Insiders

Only 0.16% of the stock of Johnson & Johnson is held by insiders.

Percentage Held by Institutions

69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JNJ Stock Analysis - Frequently Asked Questions

How have JNJ shares performed this year?

Johnson & Johnson's stock was trading at $144.62 at the start of the year. Since then, JNJ shares have increased by 34.0% and is now trading at $193.8320.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its earnings results on Wednesday, August, 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a trailing twelve-month return on equity of 33.08%.

Does Johnson & Johnson have any subsidiaries?

The following companies are subsidiaries of Johnson & Johnson: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and others.

Who are Johnson & Johnson's major shareholders?

Top institutional shareholders of Johnson & Johnson include Assenagon Asset Management S.A. (0.18%), Swedbank AB (0.09%), PineStone Asset Management Inc. (0.09%) and Fort Washington Investment Advisors Inc. OH (0.06%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Peter Fasolo, William Hait, Kathryn E Wengel, Ashley Mcevoy, Thibaut Mongon, Joseph J Wolk, Robert J Decker, Timothy Schmid, James D Swanson and Mark A Weinberger.
View institutional ownership trends.

How do I buy shares of Johnson & Johnson?

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), UnitedHealth Group (UNH), Gilead Sciences (GILD), Corning (GLW), NextEra Energy (NEE) and Devon Energy (DVN).

Company Calendar

• Last Earnings: 8/30/2023
• Record date for 9/9 Dividend: 8/26/2025
• Ex-Dividend for 9/9 Dividend: 8/26/2025
• Dividend Payable: 9/09/2025
• Today: 10/20/2025
• Record date for 12/9 Dividend: 11/25/2025
• Ex-Dividend for 12/9 Dividend: 11/25/2025
• Dividend Payable: 12/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:JNJ
• CIK: 200406
• Web: www.jnj.com
• Phone: (732) 524-0400
• Fax: 732-214-0332
• Employees: 138,100
• Year Founded: 1886

Price Target and Rating

• Average Price Target for Johnson & Johnson: $200.06
• High Price Target: $215.00
• Low Price Target: $153.00
• Potential Upside/Downside: +3.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.36
• Trailing P/E Ratio: 18.63
• Forward P/E Ratio: 18.24
• P/E Growth: 2.27
• Net Income: $14.07 billion
• Net Margins: 27.26%
• Pretax Margin: 34.19%
• Return on Equity: 33.08%
• Return on Assets: 13.30%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.01
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: $88.82 billion
• Price / Sales: 5.23
• Cash Flow: $13.10 per share
• Price / Cash Flow: 14.73
• Book Value: $29.69 per share
• Price / Book: 6.50

Miscellaneous

• Outstanding Shares: 2,408,340,000
• Free Float: 2,404,486,000
• Market Cap: $464.87 billion
• Optionable: Optionable
• Beta: 0.40